98 related articles for article (PubMed ID: 37337388)
1. Sublingual Dissolving Microneedle (SLDMN)-Based Vaccine for Inducing Mucosal Immunity against SARS-CoV-2.
Kim Y; Park IH; Shin J; Choi J; Jeon C; Jeon S; Shin JS; Jung H
Adv Healthc Mater; 2023 Oct; 12(26):e2300889. PubMed ID: 37337388
[TBL] [Abstract][Full Text] [Related]
2. Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10.
Kimoto T; Sakai S; Kameda K; Morita R; Takahashi E; Shinohara Y; Kido H
Influenza Other Respir Viruses; 2023 Mar; 17(3):e13119. PubMed ID: 36909295
[TBL] [Abstract][Full Text] [Related]
3. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
4. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
6. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
7. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
8. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
[TBL] [Abstract][Full Text] [Related]
10. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
[TBL] [Abstract][Full Text] [Related]
11. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice.
Ashhurst AS; Johansen MD; Maxwell JWC; Stockdale S; Ashley CL; Aggarwal A; Siddiquee R; Miemczyk S; Nguyen DH; Mackay JP; Counoupas C; Byrne SN; Turville S; Steain M; Triccas JA; Hansbro PM; Payne RJ; Britton WJ
Nat Commun; 2022 Nov; 13(1):6972. PubMed ID: 36379950
[TBL] [Abstract][Full Text] [Related]
12. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
13. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.
Hwang IC; Valeriano VD; Song JH; Pereira M; Oh JK; Han K; Engstrand L; Kang DK
Microb Cell Fact; 2023 May; 22(1):96. PubMed ID: 37161468
[TBL] [Abstract][Full Text] [Related]
15. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
16. Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus Vaccination in Pregnancy: Implications for Maternal and Infant Immunity.
Conti MG; Terreri S; Terrin G; Natale F; Pietrasanta C; Salvatori G; Brunelli R; Midulla F; Papaevangelou V; Carsetti R; Angelidou A
Clin Infect Dis; 2022 Aug; 75(Suppl 1):S37-S45. PubMed ID: 35535796
[TBL] [Abstract][Full Text] [Related]
17. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
Fröberg J; Diavatopoulos DA
Curr Opin Infect Dis; 2021 Jun; 34(3):181-186. PubMed ID: 33899752
[TBL] [Abstract][Full Text] [Related]
18. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.
Mouro V; Fischer A
Mucosal Immunol; 2022 Apr; 15(4):584-594. PubMed ID: 35505121
[TBL] [Abstract][Full Text] [Related]
19. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
[TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
